Sai Life Sciences Ltd

- Sai Life Sciences plans to fund its FY27 capex of INR1,100 to 1,300 crores through a mix of internal accruals and debt. - No specific details or amounts regarding new debt issuance have been disclosed. - The company expects its debt-to-EBITDA ratio to remain healthy despite increased capex and possible debt. - There is no mention of any planned equity fundraising in the provided excerpts. - Capex is primarily for capacity expansion and capability building, including CDMO and CRO segments. - The company will continue to calibrate the pace and phasing of investments based on evolving business conditions and customer demand.

- FY27 capex guidance: INR 1,100 crores to INR 1,300 crores, funded via internal accruals and debt. - Capex split: 75% towards capacity expansion (including 700 KL to 1,150 KL plant expansion and doubling process R&D capacity), 25% towards capability building and AI/digital technology. - Brownfield expansions expected to take 12-18 months; greenfield sites may take 24-30 months. - Peptide and ADC development capabilities are part of the current capex. - Investments driven by clear demand visibility and strategic conversations with large pharma clients. - AI/digital transformation investment includes intangible software/tools aiming to enhance productivity and data integration. - Capex for new site expected to start late FY27 or early FY28. - Capex approach is science-led, emphasizing flexibility and high long-term returns rather than capacity-heavy expansion.

- Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores). - Growth in the short term will likely be driven by pharma clients, with biotech contributions expected to return to a balanced 50/50 mix long-term. - CDMO segment showed strong 30%+ growth in FY26; growth outlook for FY27 and FY28 remains strong. - Increased capex (~INR 1,100-1,300 crores) focused on capacity expansion (75%) and capability/technology (25%) to support volume growth. - Revenue visibility has improved through long-term collaborations and added large pharma customers. - Long-term volume growth will be enabled by expanding discovery, development, and commercial manufacturing capabilities. - Biotech funding recovery and strategic pharma outsourcing expected to support sustained growth. - Expect a stronger second half in FY27, guided by phasing of new capacity and commercial product ramp-up.

- Sai Life Sciences projects revenue CAGR of 15% to 20% over the next few years. - EBITDA margins are targeted to be maintained in the steady-state range of 28% to 30% within a 2-3 year timeframe. - The company expects some short-term dips in asset turnover due to accelerated capex but aims for a medium-term asset turn of 1.2 to 1.4 times. - Capex of INR1,100 to 1,300 crores is planned for fiscal 2027, focused on capacity expansion (75%) and capability/technology upgrades (25%). - FY27 second half is expected to be stronger than the first half, reflecting growth ramp-up. - Profit after tax (PAT) growth was over 100% in fiscal 2026, indicating strong earnings momentum. - Long-term outlook remains strong, driven by pharma-led growth and balanced pharma/biotech revenue mix targeting 50/50 split.

- The transcript does not explicitly mention the exact current or expected order book or pending orders in terms of value or volume. - However, it indicates strong visibility and confidence into FY27 growth based on customer conversations. - The company has seen increased late-stage and mid-stage development outsourcing from large pharma, enhancing pipeline visibility. - Customers are providing better visibility of their pipelines, indicating more programs likely to translate into commercial manufacturing within 12-15 months. - The company has added multiple new commercial molecules and Phase III/pre-registration molecules, suggesting a healthy and expanding order pipeline. - Integrated CDMO and CRO engagements with large pharma and biotech customers are increasing, supporting a robust demand outlook. - Overall, while exact order book figures are not stated, the company expresses optimism based on long-term strategic partnerships and expanding capacity.